{"id":4524,"date":"2025-03-31T18:12:11","date_gmt":"2025-03-31T18:12:11","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/idarubicin-hydrochloride-txt\/"},"modified":"2025-03-31T18:12:11","modified_gmt":"2025-03-31T18:12:11","slug":"idarubicin-hydrochloride-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/idarubicin-hydrochloride-txt\/","title":{"rendered":"idarubicin hydrochloride.txt"},"content":{"rendered":"

idarubicin hydrochloride <\/h1>\n

CLINICAL USE <\/H3>
\nAntineoplastic agent:Acute non-lymphoblastic leukaemia (ANLL)2nd line for acute lymphoblastic leukaemia (ALL), breast cancer With other cytotoxic agents in combination chemotherapy regimens

DOSE IN NORMAL RENAL FUNCTION <\/H3>IV: ANLL: 12 mg\/m \u20142 daily for 3 days in combination with cytarabine, or 8 mg\/m2 daily for 5 days with or without combination therapyALL: 12 mg\/m \u20142 daily for 3 daysOral: ANLL: 30 mg\/m \u20142 daily for 3 days as a single agent, or 15\u201330 mg\/m2 daily for 3 days in combination with other anti-leukaemic agentsBreast cancer: 45 mg\/m 2 given either as a single dose or divided over 3 consecutive days every 3\u20134 weeksMaximum cumulative dose is 400 mg\/m 2 dailyOr see local protocol

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :534<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :97<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 1\u20132 (4.6% as idarubicinol)<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :64<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :10\u201335 (oral), 15 (IV)

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Use 75% of dose
  • 10 to 20 &nbsp &nbsp : Use 75% of dose with caution
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Use 50% of dose with caution

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsOther myelosuppressant medication and radiotherapy: increased risk of myelosuppression

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>5 mL water for injection per 5 mg

    Route <\/H4>IV, oral, intravesical

    Rate of Administration <\/H4>Give via the tubing of a fast running intravenous infusion of sodium chloride 0.9% or glucose 5%, over 5\u201310 minutes

    Comments<\/H4>Incompatible with alkaline solutions and heparinReconstituted solution is physically and chemically stable for 7 days at 2\u20138\u00b0C and 72 hours at room temperatureDoes not contain any antibacterial preservative so maximum recommended stability is 24 hours

    OTHER INFORMATION <\/H4>May cause the urine to become red for 1\u20132 days after administrationMetabolised to an active metabolite, idarubicinol, which has a half-life of 33\u201360 hours (oral), 41\u201369 (IV). It is eliminated by renal and hepatobiliary excretionidarubicin hydrochloride.370 IDARUbICIN HYDROCHLORIDeOral bioavailability is 18\u201339%, 29\u201358% for idarubicinol17% (IV)\/8% (oral) is recovered in the faeces over 5 days and 16% (IV)\/5% (oral) is recovered in the urine over 4 daysA phase II study instilled 6.25\u201312.5 mg of idarubicin diluted in 45 mL of sodium chloride 0.9% (0.125\u20130.25 mg\/mL) into the bladder of patients with resected recurrent bladder cancer although it may not be any more effective than doxorubicin or epirubicin and toxicity may limit its use.
    \n","protected":false},"excerpt":{"rendered":"

    idarubicin hydrochloride CLINICAL USE Antineoplastic agent:Acute non-lymphoblastic leukaemia (ANLL)2nd line<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4524","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4524"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4524\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4524"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4524"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}